bluuebunny/crossref_metadata_2025_split huggingface dataset:
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Authors: Liu Geoffrey , Tu Dongsheng , Lewis Marcia , Cheng Dangxiao , Sullivan Leslie A. , Chen Zhuo , Morgen Eric , Simes John , Price Timothy J. , Tebbutt Niall C. , Shapiro Jeremy D. , Jeffery G. Mark , Mellor J. Daniel , Mikeska Thomas , Virk Shakeel , Shepherd Lois E. , Jonker Derek J. , O'Callaghan Christopher J. , Zalcberg John R. , Karapetis Christos S. , Dobrovic Alexander 
Published: May 2016

AbstractPurpose: Two germline Fc-γ receptor (FCGR) polymorphisms, rs1801274 [FCGR2A;His(H)131Arg(R)] and rs396991 [FCGR3A;Phe(F)158Val(V)] produce altered proteins through amino acid substitutions; both are reported to be associated with cetuximab-related outcomes. We performed a validation of these polymorphisms in NCIC CTG CO.17, a randomized trial of cetuximab monotherapy in refractory, metastatic colorectal cancer expressing EGFR.Experimental Design: DNA extracted from formalin-fixed paraffin-embedded tissue was genotyped. In addition to log-rank tests, Cox proportional hazard models assessed their relationships with overall (OS) and progression-free survival (PFS), adjusting for clinically important prognostic factors, along with a polymorphism–treatment arm interaction term.Results: Somatic KRAS status was wild-type for exon 2 in 153 (52%) of 293 patients, from whom tumor DNA was available. For FCGR2A H/H, a genotype–treatment interaction for KRAS wild-type patients was observed for OS (P = 0.03). In KRAS wild-type patients carrying FCGR2A H/H, cetuximab (vs. no cetuximab) improved survival substantially, with adjusted HRs (aHR) of 0.36 (OS) and 0.19 (PFS) and absolute benefits of 5.5 months (OS; P = 0.003) and 3.7 months (PFS; P = 0.02). In contrast, patients carrying FCGR2A R alleles (H/R or R/R) had aHRs of only 0.78 (OS; 2.8-month benefit) and 0.53 (PFS; 1.6-month benefit). No relationships were found for rs396991 (FCGR3A).Conclusions: In the CO.17 trial, cetuximab worked best for patients with KRAS wild-type colorectal cancers carrying FCGR2A H/H genotypes. Significantly lower benefits were observed in patients carrying germline FCGR2A R alleles. Clin Cancer Res; 22(10); 2435–44. ©2016 AACR.
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
Authors: Okazaki Satoshi , Loupakis Fotios , Stintzing Sebastian , Cao Shu , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Stremitzer Stefan , Matsusaka Satoshi , Berger Martin D. , Parekh Anish , West Jordan D. , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Cremolini Chiara , Falcone Alfredo , Heinemann Volker , DePaolo R. William , Lenz Heinz-Josef 
Published: May 2016

Abstract
The purpose of this study was to evaluate the clinical significance of single-nucleotide polymorphisms in TLR1, TLR2, TLR6, and TAK1 in patients with metastatic colorectal cancer (mCRC). We genotyped 9 SNPs of TLR1, TLR2, TLR6, and TAK1 in mCRC patients treated with first-line FOLFIRI (combination therapy of irinotecan, 5-fluorouracil, and folinic acid) plus bevacizumab, using a discovery cohort (TRIBE trial, n = 228) and a validation cohort (FIRE-3 trial, n = 297), and analyzed for the association with response rate (RR), progression-free survival (PFS), and overall survival (OS). There was a significant association of TLR1 rs5743618 (T1805G) with the clinical outcome. In the TRIBE cohort, a homozygous wild-type genotype (T/T) associated with a significantly lower RR compared with variant T/G and G/G genotypes (43% vs. 62%, P = 0.025), and this observation was validated in the FIRE-3 cohort (46% vs. 65%, P = 0.021). In addition, those patients with the T/T genotype had significantly worse PFS (median, 8.2 vs. 10.5 months; HR, 1.57; 95% CI, 1.09–2.28, P = 0.014) and OS (median: 19.9 vs. 27.9 months; HR, 1.63; 95% CI, 1.14–2.35, P = 0.007), compared with those with other genotypes in the TRIBE cohort. These differences remained statistically significant in multivariate analysis. Our data suggest that TLR1 rs5743618 could serve as a predictor of clinical response to FOLFIRI plus bevacizumab in patients with mCRC. Mol Cancer Ther; 15(7); 1740–5. ©2016 AACR.
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin
Authors: Whitlock Richard P. , Fordyce Christopher B. , Midei Mark G. , Ellis Dave , Garcia David , Weitz Jeffrey I. , Canafax Daniel M. , Albrecht Detlef , Milner Peter G. 
Published: May 2016

SummaryTecarfarin is a novel vitamin K antagonist that is metabolised by carboxyl estererase, thereby eliminating the variability associated with cytochrome-mediated metabolism. EmbraceAC was designed to compare the quality of anticoagulation with tecarfarin and warfarin as determined by time in therapeutic range (TTR). In this phase 2/3 randomised and blinded trial, 607 patients with indications for chronic anticoagulation were assigned to warfarin (n=304) or tecarfarin (n=303). Dosing of study drugs was managed by a centralised dose control centre, which had access to genotyping. The primary analysis tested superiority of tecarfarin over warfarin for TTR. Patients were recruited between May 12, 2008 and May 12, 2009. TTR with tecarfarin and warfarin were similar (72.3% and 71.5%, respectively; p=0.51). In those taking CYP2C9 interacting drugs, the TTR on tecarfarin (n=92) was similar to that on warfarin (n=87, 72.2% and 69.9%, respectively; p=0.15). In patients with mechanical heart valves, the TTR of tecarfarin (n=42) was similar to that of warfarin (n=42, 68.4% and 66.3%, respectively; p=0.51). The same was true for the TTR in patients with any CYP2C9 variant allele and on CYP2C9-interacting drugs (tecarfarin, n=24, 76.5% vs warfarin, n=31, 69.5%; p=0.09). There was no difference in thromboembolic or bleeding events. In conclusion, superiority of tecarfarin over warfarin for TTR was not demonstrated. The TTR with tecarfarin was similar to that with well-controlled warfarin and tecarfarin appeared to be safe and well tolerated with few major bleeding and no thrombotic events. Favourable trends in certain subpopulations make tecarfarin a promising oral anticoagulant that deserves further study.Supplementary Material to this article is available online at www.thrombosis-online.com.
Interleukin-33 stimulates GM-CSF and M-CSF production by human endothelial cells
Authors: Montanari Eliana , Stojkovic Stefan , Kaun Christoph , Lemberger Christof E. , de Martin Rainer , Rauscher Sabine , Gröger Marion , Maurer Gerald , Neumayer Christoph , Huk Ihor , Huber Kurt , Demyanets Svitlana , Wojta Johann 
Published: May 2016

SummaryInterleukin (IL)-33, a member of the IL-1 family of cytokines, is involved in various inflammatory conditions targeting amongst other cells the endothelium. Besides regulating the maturation and functions of myeloid cells, granulocyte macrophage-colony stimulating factor (GM-CSF) and macrophage-CSF (M-CSF) have been shown to play a role in such pathologies too. It was the aim of our study to investigate a possible influence of IL-33 on GM-CSF and M–CSF production by human endothelial cells. IL-33, but not IL-18 or IL-37, stimulated GM-CSF and M-CSF mRNA expression and protein production by human umbilical vein endothelial cells (HUVECs) and human coronary artery ECs (HCAECs) through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway in an IL–1-independent way. This effect was inhibited by the soluble form of ST2 (sST2), which is known to act as a decoy receptor for IL-33. The 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor fluvastatin could also be shown to moderately reduce the IL-33-mediated effect on M-CSF, but not on GM-CSF expression. In addition, IL–33, IL-1β, GM-CSF and M-CSF were detected in endothelial cells of human carotid atherosclerotic plaques using immunofluorescence. Upregulation of GM-CSF and M–CSF production by human endothelial cells, an effect that appears to be mediated by NF–κB and to be independent of IL-1, may be an additional mechanism through which IL-33 contributes to inflammatory activation of the vessel wall.Supplementary Material to this article is available online at www.thrombosis-online.com.
ПОРІВНЯЛЬНИЙ АНАЛІЗ РЕЗУЛЬТАТІВ ЯКІСНОЇ УСПІШНОСТІ СТУДЕНТІВ ПРИ ПРОВЕДЕННІ ПІДСУМКОВОГО МОДУЛЬНОГО КОНТРОЛЮ
Authors: Kuzmenko O. V. , Konovalenko S. O. 
Published: May 2016

<p>У статті проаналізована якісна успішність студентів медичного коледжу з дисципліни «Анатомія людини» за підсумками пілотного тестового контролю як незалежного кінцевого етапу оцінювання, та двохетапної системи підсумкового модульного контролю (тестування та практичні навички). </p>
Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus
Authors: Kaasenbrood Lotte , Poulter Neil R. , Sever Peter S. , Colhoun Helen M. , Livingstone Shona J. , Boekholdt S. Matthijs , Pressel Sara L. , Davis Barry R. , van der Graaf Yolanda , Visseren Frank L.J. 
Published: May 2016

Background—
In this study, we aimed to translate the average relative effect of statin therapy from trial data to the individual patient with type 2 diabetes mellitus by developing and validating a model to predict individualized absolute risk reductions (ARR) of cardiovascular events.

Methods and Results—

Data of 2725 patients with type 2 diabetes mellitus from the Lipid Lowering Arm of the Anglo Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) study (atorvastatin 10 mg versus placebo) were used for model derivation. The model was based on 8 clinical predictors including treatment allocation (statin/placebo). Ten-year individualized ARR on major cardiovascular events by statin therapy were calculated for each patient by subtracting the estimated on-treatment risk from the estimated off-treatment risk. Predicted 10-year ARR by statin therapy was <2% for 13% of the patients. About 30% had an ARR of >4% (median ARR, 3.2%; interquartile range, 2.5%–4.3%; 95% confidence interval for 3.2% ARR, –1.4% to 6.8%). Addition of treatment interactions did not improve model performance. Therefore, the wide distribution in ARR was a consequence of the underlying distribution in cardiovascular risk enrolled in these trials. External validation of the model was performed in data from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT; pravastatin 40 mg versus usual care) and Collaborative Atorvastatin Diabetes Study (CARDS; atorvastatin 10 mg versus placebo) of 3878 and 2838 patients with type 2 diabetes mellitus, respectively. Model calibration was adequate in both external data sets, discrimination was moderate (ALLHAT-LLT:
c
-statistics, 0.64 [95% confidence interval, 0.61–0.67] and CARDS: 0.68 [95% confidence interval, 0.64–0.72]).

Conclusions—
ARRs of major cardiovascular events by statin therapy can be accurately estimated for individual patients with type 2 diabetes mellitus using a model based on routinely available patient characteristics. There is a wide distribution in ARR that may complement informed decision making.

Clinical Trial Registration—

URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00327418 (CARDS) and NCT00000542 (ALLHAT).
Coleophora ericarnella Baldizzone, a new species of the C. pyrrhulipennella group (Lepidoptera: Coleophoridae) from the South-Eastern Alps
Authors: BALDIZZONE GIORGIO , LANDRY JEAN-FRANÇOIS 
Published: May 2016

Coleophora ericarnella Baldizzone, n. sp. is described from the East-Central Alps region (Italy and Slovenia). It belongs to the C. pyrrhulipennella group. Its larval host plant is Erica carnea (Ericaceae). The adult habitus and genitalia as well as its larval case are illustrated and compared with those of Coleophora pulchripennella Baldizzone, 2011 and C. pyrrhulipennella Zeller, 1849. DNA barcodes also distinguish all three species from each other in congruence with genitalia morphology.
Completion lobectomy after radical segmentectomy for pulmonary malignancies
Authors: Omasa Mitsugu , Date Hiroshi , Takamochi Kazuya , Suzuki Kenji , Miyata Yoshihiro , Okada Morihito 
Published: May 2016

Objective Completion lobectomy after radical segmentectomy is relatively rare, with no systematic evaluation of this challenging procedure. We aimed to clarify the details of this operation performed in 3 Japanese institutions. Methods Completion lobectomy after segmentectomy in the same lobe was performed in 11 patients (9 lung cancers and 2 metastatic lung tumors) between 2007 and 2013. Surgical outcomes were analyzed retrospectively. Results The 11 patients accounted for 1.37% of the 805 segmentectomies performed in the 3 institutions. The reasons for completion lobectomy were postoperative complications in the remaining lobe ( n = 3), positive pathological lymph node metastasis found by permanent section ( n = 3), and malignancy in the remaining lobe ( n = 5). The patients were divided into two groups according the interval between segmentectomy and completion lobectomy: group A (3–35 days, n = 5) and group B (56–1470 days, n = 6). There was a tendency for more severe adhesions around the hilum ( p = 0.061) in group B, resulting in increased operative bleeding ( p = 0.055), more usage of fibrin glue ( p = 0.080), and significantly longer operative time ( p = 0.036). Injury to the pulmonary arteries was experienced only in group B (3/6 cases). There was no operation-related mortality. Conclusions Completion lobectomy may become more difficult approximately 5 weeks after segmentectomy, due to severe adhesions, but it can be performed safely with careful manipulation.
Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model
Authors: Becattini Cecilia , Agnelli Giancarlo , Lankeit Mareike , Masotti Luca , Pruszczyk Piotr , Casazza Franco , Vanni Simone , Nitti Cinzia , Kamphuisen Pieter , Vedovati Maria Cristina , De Natale Maria Grazia , Konstantinides Stavros 
Published: May 2016

The European Society of Cardiology (ESC) has proposed an updated risk stratification model for death in patients with acute pulmonary embolism based on clinical scores (Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI)), right ventricle dysfunction (RVD) and elevated serum troponin (2014 ESC model).We assessed the ability of the 2014 ESC model to predict 30-day death after acute pulmonary embolism. Consecutive patients with symptomatic, confirmed pulmonary embolism included in prospective cohorts were merged in a collaborative database. Patients’ risk was classified as high (shock or hypotension), intermediate-high (RVD and elevated troponin), intermediate-low (RVD or increased troponin or none) and low (sPESI 0). Study outcomes were death and pulmonary embolism-related death at 30 days.Among 906 patients (mean±sdage 68±16, 489 females), death and pulmonary embolism-related death occurred in 7.2% and 4.1%, respectively. Death rate was 22% in “high-risk” (95% CI 14.0–29.8), 7.7% in “intermediate-high-risk” (95% CI 4.5–10.9) and 6.0% in “intermediate-low-risk” patients (95% CI 3.4–8.6). One of the 196 “low-risk” patients died (0.5%, 95% CI 0–1.0; negative predictive value 99.5%).By using the 2014 ESC model, RVD or troponin tests would be avoided in about 20% of patients (sPESI 0), preserving a high negative predictive value. Risk stratification in patients at intermediate risk requires further improvement.
Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer
Authors: Irie Masataka , Nakanishi Ryoichi , Yasuda Manabu , Fujino Yoshihisa , Hamada Kazumi , Hyodo Masahiro 
Published: May 2016

Few studies have analysed postoperative risk factors in patients undergoing thoracoscopic lobectomy, including assessments of preoperative physical function. The objectives of this study were to identify predictors of postoperative deterioration of performance status and cardiopulmonary complications in cases of thoracoscopic lobectomy.Between June 2005 and October 2012, we retrospectively reviewed 188 consecutive subjects who underwent thoracoscopic lobectomy for preoperative stage I nonsmall cell lung cancer. The demographic and clinical parameters, including physical function, were analysed using a multivariate logistic regression to clarify the determinants.The percent predicted diffusing capacity of the lung for carbon monoxide, quadriceps muscle strength and pathologic stage were independent risk factors for deterioration of performance status after surgery in the multivariate analyses. Chronic obstructive pulmonary disease, 6-min walking distance and pathologic stage were also independent risk factors for postoperative cardiopulmonary complications.Our data suggest that, in addition to a greater pathologic stage, lower diffusing capacity and comorbid chronic obstructive pulmonary disease, poor physical function was associated with worse short-term outcomes after thoracoscopic lobectomy. An evaluation of preoperative quadriceps muscle strength and 6-min walk test is easily performed and may therefore be a useful predictor in cases of thoracoscopic lobectomy.
Ketamine: stimulating antidepressant treatment?
Authors: Malhi Gin S. , Byrow Yulisha , Cassidy Frederick , Cipriani Andrea , Demyttenaere Koen , Frye Mark A. , Gitlin Michael , Kennedy Sidney H. , Ketter Terence A. , Lam Raymond W. , McShane Rupert , Mitchell Alex J. , Ostacher Michael J. , Rizvi Sakina J. , Thase Michael E. , Tohen Mauricio 
Published: May 2016

SummaryThe appeal of ketamine – in promptly ameliorating depressive symptoms even in those with non-response – has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression and provide a synthesis of perspectives – derived from evidence and clinical experience – and to consider strategies for future investigations.
A review of the evidence for adjustable compression wrap devices
Authors: Williams A. 
Published: May 2016

Compression therapy is a key component in the effective management of people with lower limb problems associated with venous, lymphatic and fat disorders such as lipoedema. Individuals with lymphoedema, venous ulceration and lipoedema often require long-term compression therapy to prevent and manage problems such as chronic ulceration and skin changes, persistent swelling and shape distortion. Challenges remain in achieving acceptable, safe, effective and cost-efficient compression therapy choices. Adjustable compression wrap devices using hook and loop fasteners, commonly called VELCRO brand fasteners, present new opportunities for improving treatment outcomes, supporting patient independence and self-management in the use of compression therapy. This paper reports the findings of an evidence review of adjustable compression wrap devices in people with lymphoedema, chronic oedema, venous ulceration and lipoedema. Declaration of interest: The authors have no conflict of interest to declare.
An open, non-comparative, multicentre evaluation of performance and safety using an antimicrobial exudate transfer dressing on diabetic foot ulcers: a case series
Authors: Dhatariya K. , Gooday C. , Franke B. , Pilling T. , Flanagan A. , Zeidan L. 
Published: May 2016

Objective: To evaluate the performance and safety of Mepilex Transfer Ag (MTAg) in the treatment of infected diabetic foot ulcers (DFU). Method: Patients with locally infected DFU were treated with the test dressing for up to 4 weeks, with a further 12 weeks of follow-up in a non-comparative study. Changes to wound infection and wound size as well as the condition of the peri-wound skin from baseline were assessed. Wound pain during dressing change was measured using a visual analogue scale (VAS). The investigators and patients documented their opinions on their overall experience of the test dressing and on key performance parameters. Results: Following treatment with the test dressing, the signs and symptoms of local wound infection present in the target DFU were substantially reduced compared with baseline. Following the posttreatment evaluation, the majority of the DFU exhibited no signs of infection. and mean wound size was reduced by 50%. Wound size also continued to steadily decrease during follow-up. At the end of treatment five DFUs were completely healed and a further six healed by the end of the follow-up period. Concomitantly, over the course of the study, wound exudate levels were reduced and there was a significant improvement in the condition of the peri-wound area. Wound pain at dressing change was low throughout; generally patients felt no anxiety during the dressing change procedure. The patients considered it a comfortable dressing that remained in place and allowed ease of movement during wear. The investigating clinicians were highly satisfied with the overall performance, especially with respect to its ease of application and removal, conformability and flexibility. Conclusion: This study has demonstrated the potential of the dressing to provide topical antimicrobial activity directly to an infected DFU, suggesting prompt treatment of an infected DFU with this topical antimicrobial could aid wound complications. Declaration of interest: The authors have no conflict of interest to declare.
Influence of Sugar Palm Ash Fraction and Resonator Configuration on Acoustic Absorption Performance of Expose Brick
Authors: R Zulfa Kamila , Yahya Iwan , U Utari 
Published: May 2016

<span>Sound absorption performance optimization of expose brick has been conducted in associated with <span>the fraction of sugar palm ash in its raw material and configuration of Helmholtz resonators inside <span>the brick structure. The testing was conducted experimentally refer to ASTM E-1050-98 standard <span>procedure. In this case there are three variations sugar palm ash fractions of 0%, 5%, and 10%, as <span>well as two array resonator configurations. The results showed that the brick with fraction of 10% <span>sugar palm ash has the best sound absorption performance. As for the configuration of array <span>identical Helmholtz resonator giving better performance improvement at low frequency span than <span>complex resonator structure with coupled cavity where the best performance occur on(376-488) <span>Hz frequency range with the absorption coefficient α of 0.54.</span></span></span></span></span></span></span></span><br /></span>
Study of Macrobending Losses Effect in Plastic Optical Fibber.
Authors: Ghozali Egyn Furqon , Yunianto Mohtar , N Nuryani 
Published: May 2016

<span>Experimental study to analyze the effect of macrobending losses in plastic optical fiber triple bending <span>model based on PC (personal computer) has been conducted. The data is gathered by measuring the <span>change of the light intensity due to the presence of bending on optical fibers. The bending causes losses <span>of optical fiber that is read by WIM (weight in motion) Acquisition program based on Borlan Delphi 7. <span>The optical fibers are plastic with diameter of 3 mm. The diameter of pin is 8 mm and the space between <span>the pin is 5 mm. The light source is a LED (<span><em>λ</em><span>=676 nm). As a result, the losses of optical fiber increase <span>with the enhancement of bending. The increase trend linear to sensitivity of the sensor with gradient of <span>0,1063 and <span><em>R</em><span>2 <span>of 0,9626. Therefore, the proposed design might be applied as a WIM sensor.</span></span></span></span></span></span></span><br /></span></span></span></span></span></span>